CDK4 and familial pancreatic carcinoma: In a case study of a pancreatic cancer patient who initially responded but subsequently progressed on trametinib and the autophagy inhibitor hydroxychloroquine, developing c-MYC amplification and CDK4/6 up-regulation, a biochemical response was obtained with the combination of palbociclib with hydroxychloroquine [60].